Search results
Results from the WOW.Com Content Network
Dose change rules are as follows: [citation needed] Twice a week a full blood count with white blood cell count (WBC) differential is obtained. Dose escalation above the starting doses in case of good patient's chemotherapy tolerability applies simultaneously to etoposide, doxorubicin and cyclophosphamide.
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
R-miniCHOP is indicated in elderly patients (>80 years) with diffuse large B-cell lymphoma due to less toxicity from the reduced dose in comparison to R-CHOP.. R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine).
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
The comparator arm received 6 cycles of B+R (bendamustine 70 mg/m2 on days 1 and 2 of each 28-day cycle and rituximab at the above described dose and schedule). [17] The application for venetoclax in combination with rituximab was granted priority review along with a breakthrough therapy designation. [17]
More recently, the immunotherapy drug, rituximab has been added to the CHOP chemotherapy regiment to form the R-CHOP chemoimmunotherapy regimen. [2] Rituximab is a monoclonal antibody that binds to the CD20 protein on, e.g. B-cells, and by doing so targets these cells for attack by the hosts adaptive immune system. [13]
High dose: cerebral and cerebellar dysfunction, ocular toxicity, pulmonary toxicity, severe GI ulceration and peripheral neuropathy (rare). Decitabine: IV: DNA methyltransferase inhibitor. Myelodysplastic syndrome, sickle cell anaemia (orphan), acute myeloid leukaemia and chronic myeloid leukaemia.
Treatment commonly begins with either R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab). [14] Other, more intense, regimens may be more effective. [10] PD-1 and PD-L1 inhibitors can be used. [3]